Onsdag 12 Mars | 12:23:03 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-02-26 08:30 Bokslutskommuniké 2025
2025-11-28 08:30 Kvartalsrapport 2025-Q3
2025-08-28 08:30 Kvartalsrapport 2025-Q2
2025-06-19 N/A X-dag ordinarie utdelning AXIC A 0.00 SEK
2025-06-18 N/A Årsstämma
2025-05-22 08:30 Kvartalsrapport 2025-Q1
2025-02-27 - Bokslutskommuniké 2024
2024-11-28 - Kvartalsrapport 2024-Q3
2024-08-27 - Kvartalsrapport 2024-Q2
2024-06-20 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2024-06-19 - Årsstämma
2024-05-23 - Kvartalsrapport 2024-Q1
2024-03-06 - Extra Bolagsstämma 2024
2024-03-05 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-19 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2023-06-16 - Årsstämma
2023-05-24 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-01 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2022-05-31 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-31 - Kvartalsrapport 2021-Q2
2021-05-31 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2021-05-28 - Årsstämma
2021-05-20 - Kvartalsrapport 2021-Q1
2021-02-24 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2020-05-26 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-29 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2019-05-28 - Årsstämma
2019-05-23 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-06-01 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2018-05-31 - Årsstämma
2018-05-15 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-06-01 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2017-05-31 - Årsstämma
2017-05-31 - Kvartalsrapport 2017-Q1
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016
2016-11-24 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-24 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2016-05-23 - Årsstämma
2016-05-19 - Kvartalsrapport 2016-Q1
2016-02-25 - Bokslutskommuniké 2015
2015-11-25 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
2015-05-29 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2015-05-28 - Årsstämma
2015-05-25 - Kvartalsrapport 2015-Q1
2015-02-26 - Bokslutskommuniké 2014
2014-11-24 - Kvartalsrapport 2014-Q3
2014-08-28 - Kvartalsrapport 2014-Q2
2014-05-22 - Årsstämma
2014-05-22 - Kvartalsrapport 2014-Q1
2014-02-28 - Bokslutskommuniké 2013
2013-11-29 - Kvartalsrapport 2013-Q3
2013-08-26 - Kvartalsrapport 2013-Q2
2013-06-28 - Split AXIC A 4:1
2013-05-30 - Kvartalsrapport 2013-Q1
2013-05-21 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2013-05-20 - Årsstämma
2013-02-28 - Bokslutskommuniké 2012
2012-11-26 - Kvartalsrapport 2012-Q3
2012-08-30 - Kvartalsrapport 2012-Q2
2012-05-28 - Kvartalsrapport 2012-Q1
2012-05-17 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2012-05-16 - Årsstämma
2012-02-29 - Bokslutskommuniké 2011
2011-11-28 - Kvartalsrapport 2011-Q3
2011-08-30 - Kvartalsrapport 2011-Q2
2011-05-30 - Kvartalsrapport 2011-Q1
2011-05-10 - X-dag ordinarie utdelning AXIC A 0.00 SEK
2011-05-09 - Årsstämma
2011-02-25 - Bokslutskommuniké 2010
2010-05-11 - X-dag ordinarie utdelning AXIC A 0.00 SEK

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorMaterial
IndustriPlast, kemikalier & fetter
aXichem är verksamt inom industriell bioteknik. Bolaget utvecklar, patenterar och marknadsför industrikemikalier. Bolaget arbetar framförallt med Fenylcapsaicin, en naturanalog syntetisk capsaicin med tillämpningar inom en mängd olika områden, såsom inom den marina sektorn, bland skadedjursbekämpning i skogs-och jordbruk, samt bland enskilda farmaceutiska arbetsområden. Verksamhet drivs på global nivå, med huvudkontoret i Malmö.
2025-03-05 09:00:00

aXichem AB (publ), (aXichem), the developer of innovative natural analogue feed additives and food supplement ingredients, announces exciting preliminary results from its latest randomized, placebo-controlled, crossover study investigating the effects of aXivite® (phenylcapsaicin) on high-intensity CrossFit performance and recovery.

This study, conducted by Dr. Pablo Jiménez Martínez and his team in Spain, is part of a government-funded doctoral research initiative aimed at enhancing performance through novel bioactive compounds. Early data confirms that aXivite® significantly improves strength, endurance, and recovery, reinforcing its commercial potential in the rapidly expanding global sports nutrition market.

Key Preliminary Findings:

  • Increased Endurance: CrossFit athletes supplementing with aXivite® maintained performance levels significantly longer than those on placebo, demonstrating increased stamina and resilience in the final rounds of high-intensity CrossFit training sessions, commonly known as 'Workout of the Day' (WODs).
  • Peak Strength Gains: Participants taking aXivite® lifted more weight, completed more repetitions, and showed greater power output, even under conditions of extreme fatigue.
  • Accelerated Recovery: Athletes supplemented with PC reported reduced muscle soreness and a faster return to peak performance, a major factor in high-performance training and sports nutrition product selection.
  • AI-Driven Data Validation: This study introduces cutting-edge AI-based within-subject analysis, an unprecedented method in performance research, further solidifying the robustness of the findings.

Dr. Jiménez Martínez, the lead researcher, emphasized the significance of these findings:

"We anticipated phenylcapsaicin would enhance performance, but the results have exceeded our expectations. Even in the most grueling phases of CrossFit training, aXivite® consistently helped athletes push beyond fatigue, making it a standout ingredient in the sports performance category. Additionally, our ongoing sex-specific analysis could further highlight unique physiological benefits. I'm looking forward to full study results, which should be published in before the summer."

Lucas Altepost, Vice President of Sales and Marketing at aXichem, comments:

"These results confirm aXivite® as a category-defining innovation in the sports nutrition space. With demand for pre-workout and endurance-enhancing supplements surging across North America and Europe, this study provides the scientific validation that leading brands are actively seeking. We expect an increasing commercial interest from supplement manufacturers eager to integrate aXivite® into next-generation performance formulas."

About CrossFit and the sports nutrition market
CrossFit has evolved into one of the fastest-growing global fitness trends, with over 15,000 affiliated gyms worldwide and millions of active participants across North America, Europe, and beyond. The sport's intense, high-performance training style has created strong demand for effective nutritional supplements. The global sports nutrition market is projected to grow from $45 billion in 2023 to over $70 billion by 2030, with high-intensity performance supplements being one of the fastest-growing categories. aXivite®is strategically positioned to capitalize on this demand, offering a clinically backed, high-performance solution to brands looking to differentiate in the crowded supplement market.

The information was submitted, through the care of the contact person below, for publication on
5 March 2025, at 9:00 AM CET.

Company contact:
Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355 Email: torsten.helsing@axichem.com

About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio- enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.

More about aXichem at www.axichem.com.